Sanofi shares rise

Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third quarter.
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its respiratory syncytial
Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full-year earnings guidance. Read more here.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company reported third-quarter sales of 13.
Sanofi profit growth beats market view on early start of vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
FiercePharma19h
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
Investor's Business Daily on MSN13h
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.
Sanofi SA (SNY) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Advances
Sanofi SA (SNY) reports a robust 16% sales increase, driven by Dupixent and vaccines, while navigating market challenges and ...
Sanofi beats expectations with bumper third-quarter earnings
Sanofi reported stronger-than-expected third-quarter earnings on Friday, driven by early vaccine sales and robust performance ...
The Pharma Letter1d
Sanofi outpaces expectations in third quarter 2024
Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.